Our website uses cookies to ensure you get the best experience with the most relevant info provided

Cardiolyse is selected for the AMGEN Challenge of 2020 EIT Health Startups Meet Pharma event

To match innovators with a task force of experts to develop commercially-viable products and services with the greatest potential for societal and economic impact in Europe this time European Institute of Innovation and Technology (EIT Health) joined forces with Amgen, Bayer, Beiersdorf AG, and Boehringer Ingelheim.

AMGEN, one of the world’s leading biotechnology companies, aimed at finding the solution to create a standardized procedure for post-MI patients after discharge, pointing out that preventing myocardial infarction (MI) in a population at risk and in patients who have already experienced an MI episode is extremely important.

Particularly, AMGEN was looking for a predictive analytics tool to identify very high-risk patients and a procedure/tool which will provide holistic support to post-MI patients after discharge.

Cardiolyse provides exactly the platform for accurate and complex remote cardiac patients monitoring with the proprietary algorithms on heart failure risk stratification.
We're excited by the delivered innovation and entrepreneurship workshops and are looking forward to furthering program collaborations!

Back to blog

Related posts

Cardiolyse crowdfunding open on Aescuvest.de

Cardiolyse shows a successful pilot project at EXPO 6 Startup Creasphere by Plug and Play

EIT Health Catapult 2021 selects Cardiolyse for the semi-final

Cardiolyse is chosen for the first edition of the Health&Biotech accelerator by Deloitte Italy

Startup Creasphere by Plug and Play selects Cardiolyse for their 3-months-program

Read more

Let’s work together
on heart health improvement